摘要
The treatments of resectable colorectal liver metastases（CRLM） are controversial. This study aimed to evaluate the relative efficacy and safety of hepatic resection（HR） and radiofrequency ablation（RFA） for treating resectable CRLM. Between January 2004 and May 2010, the enrolled patients were given hepatic resection（HR group; n=32） or percutaneous RFA（RFA group; n=21） as a first-line treatment for CRLM. All the tumors had a maximum diameter of 3.5 cm and all patients had five or less tumors. The patient background, tumor characteristics, cumulative survival rate and recurrence-free survival rate were assessed in both groups. There were significantly more patients with comorbidities in the RFA group than those in the HR group（17 in RFA group vs. 10 in HR group; P〈0.000）. The mean maximum tumor diameter in the HR group and RFA group was 2.25±0.68 and 1.89±0.62 cm（P=0.054）, and the mean number of tumors was 2.28±1.05 and 2.38±1.12（P=0.744）, respectively. The 1-, 3- and 5-year cumulative survival rates in the HR group were 87.5%, 53.1% and 31.3%, respectively, and those in the RFA group were 85.7%, 38.1% and 14.2%, respectively with the differences being not significant between the two groups（P=0.062）. The 1-, 3- and 5-year recurrence-free survival rates in the HR group were 90.6%, 56.3% and 28.1%, respectively, and those in the RFA group were 76.1%, 23.8% and 4.8%, respectively, with the differences being significant between the two groups（P=0.036）. In conclusion, as HR has greater efficacy than RFA in the treatment of resectable CRLM, we recommend it as the first option for this malignancy.
The treatments of resectable colorectal liver metastases（CRLM） are controversial. This study aimed to evaluate the relative efficacy and safety of hepatic resection（HR） and radiofrequency ablation（RFA） for treating resectable CRLM. Between January 2004 and May 2010, the enrolled patients were given hepatic resection（HR group; n=32） or percutaneous RFA（RFA group; n=21） as a first-line treatment for CRLM. All the tumors had a maximum diameter of 3.5 cm and all patients had five or less tumors. The patient background, tumor characteristics, cumulative survival rate and recurrence-free survival rate were assessed in both groups. There were significantly more patients with comorbidities in the RFA group than those in the HR group（17 in RFA group vs. 10 in HR group; P〈0.000）. The mean maximum tumor diameter in the HR group and RFA group was 2.25±0.68 and 1.89±0.62 cm（P=0.054）, and the mean number of tumors was 2.28±1.05 and 2.38±1.12（P=0.744）, respectively. The 1-, 3- and 5-year cumulative survival rates in the HR group were 87.5%, 53.1% and 31.3%, respectively, and those in the RFA group were 85.7%, 38.1% and 14.2%, respectively with the differences being not significant between the two groups（P=0.062）. The 1-, 3- and 5-year recurrence-free survival rates in the HR group were 90.6%, 56.3% and 28.1%, respectively, and those in the RFA group were 76.1%, 23.8% and 4.8%, respectively, with the differences being significant between the two groups（P=0.036）. In conclusion, as HR has greater efficacy than RFA in the treatment of resectable CRLM, we recommend it as the first option for this malignancy.
基金
supported by Research Fund of Public Welfare in Health Industry(No.201402015)
Research Fund of Molecular Imaging Key Laboratory,Hubei province,China(No.02.03.2015-151)
